مجله زنان، مامایی و نازایی ایران

مجله زنان، مامایی و نازایی ایران

بیان مارکرهای PD_1 و PDL_1 به روش ایمنوهیستوشیمی در کارسینوم‌های آندومتر و ارتباط آن با فاکتورهای کلینیکوپاتولوژیک

نوع مقاله : اصیل پژوهشی

نویسندگان
دکتر امیرحسین جعفریان 1
دکتر نعما محمدیان روشن 2
دکتر حسن مهراد مجد 3
دکتر سیده مریم کرامتی 4
1 استاد گروه آسیب‌شناسی، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.
2 دانشیار گروه آسیب‌شناسی، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.
3 استادیار گروه پزشکی مولکولی، مرکز تحقیقات پاتولوژی مولکولی سرطان، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.
4 دستیار تخصصی آسیب‌شناسی، دانشکده پزشکی، دانشگاه علوم پزشکی مشهد، مشهد، ایران.
10.22038/ijogi.2024.80445.6114
چکیده
مقدمه: پروتئین مرگ سلولی برنامه‌ریزی شده (PD-1) و لیگاند مرگ برنامه‌ریزی شده (PD-L1)، مولکول‌های تعدیل‌کننده ایمنی هستند که هدف مطالعات در کنسرهای ریه و ملانوم و کلیه بوده‌اند. مطالعه حاضر با هدف بررسی ایمونوهیستوشیمی بیان PD-1 و PDL-1 در سرطان آندومتر و ارتباط آن با یافته­ های کلینیک و پاتولوژیک انجام شد.
روش‌کار: در این مطالعه مقطعی، جامعه مورد پژوهش بیماران مبتلا به سرطان آندومتر پذیرش شده در بیمارستان قائم (عج) مشهد در بازه زمانی فروردین 1401 تا اسفند 1402 بودند. با مراجعه به پرونده پزشکی و تماس تلفنی با بیماران، اطلاعاتی در مورد سن، وضعیت تومور و حیات بیماران جمع‌آوری شد. بیان مارکرها نیز به روش ایمنوهیستوشیمی ارزیابی شد. تجزیه و تحلیل داده ­ها با استفاده از نرم‌افزار آماری SPSS (نسخه 23) و آزمون‌های کای دو، دقیق فیشر و آزمون ­های همبستگی اسپیرمن و پیرسون انجام شد. میزان p کمتر از 05/0 معنی‌دار در نظر گرفته شد.
یافته­ ها: بر اساس نتایج مطالعه، بین بیان دو مارکر PD-L1 و PD-1 و ویژگی‌های سن، نوع هیستولوژیک تومور، سایز تومور، تهاجم عروقی، تهاجم به میومتر، مرحله بیماری و بقاء ارتباط معناداری وجود نداشت (05/0<p)، با این‌حال بین عدم بیان PD-L1 و PD-1 با گرید بیماری ارتباط آماری معنی‌داری وجود داشت (05/0>p).
نتیجه­ گیری: تنها بیان منفی PD-1 و PDL-1 با درجه FIGO 1 ارتباط داشت. با توجه به نتایج این مطالعه، ارزیابی ارزش بیان مارکرهای PD-1 و PDL-1 نیازمند انجام مطالعات بیشتر با حجم نمونه بالاتر و پیگیری طولانی‌مدت می­ باشد.
کلیدواژه‌ها
ایمونوهیستوشیمی
سرطان آندومتر
PD-1
PDL-1
موضوعات

عنوان مقاله English

Expression of PD-1, PD-L1 Markers and their Relationship with Clinicopathologic Factors in Endometrial Cancer

نویسندگان English

Amir Hossein Jafarian 1
Nema Mohamadian Roshan 2
Hasan Mehrad-Majd 3
Maryam Keramati 4
1 Professor, Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
2 Associate Professor, Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3 Assistant Professor, Department of Molecular Medicine, Cancer Molecular Pathology Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
4 Resident, Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
چکیده English

Introduction: Programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are immunomodulator molecules that have been the focus of research in lung cancer, melanoma, and renal cell cancer. The present study was conducted with aim to investigate the immunohistochemical expression of PD-1 and PDL-1 in endometrial cancer and its relationship with clinical and pathological findings.
Methods: This cross-sectional study comprised 91 patients with endometrial cancer admitted to Qaem Hospital in Mashhad between April 2022 and March 2024. By referring to the medical record and calling the patients, information was collected about age, tumor status and survival of the patients. Expression of markers was assessed by immunohistochemistry method. Data analysis was done using SPSS (version 23) and chi-square, Fisher's exact, t-test and Spearman and Pearson correlation tests. P<0.05 was considered significant.
Results: There was no significant relationship between the expression of the two markers PD-1 and PD-L1 and the characteristics of age, histological type, tumor size, vascular invasion, myometrial invasion, FIGO stage and survival (p>0.05). However, there was a statistically significant correlation between the lack of expression of PD-1 and PD-L1 with the disease grade (p<0.05).
Conclusion: Negative PD-1 and PDL-1 expression correlated with FIGO grade 1. According to the findings of the present study, evaluation of the expression of PD-1 and PDL-1 markers requires further studies with larger sample size and long-term follow-up.

کلیدواژه‌ها English

Endometrial cancer
Immunohistochemistry
PD-1
PD-L1
  1. Yeganeh Z, Sheikhan Z, Hajian P, Esteki T, Nasiri M, Khodakarami N. Relationship between duration of breast feeding and endometrial cancer: a case-control study. The Iranian Journal of Obstetrics, Gynecology and Infertility 2020; 23(8):58-65.
  2. Makker V, Green AK, Wenham RM, Mutch D, Davidson B, Miller DS. New therapies for advanced, recurrent, and metastatic endometrial cancers. Gynecologic oncology research and practice 2017; 4:1-12.
  3. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up. International Journal of Gynecologic Cancer 2016; 26(1).
  4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. New England Journal of Medicine 2003; 348(17):1625-38.
  5. Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecologic oncology 2013; 129(2):277-84.
  6. Sari A, Pollett A, Eiriksson LR, Lumsden-Johanson B, Van de Laar E, Kazerouni H, et al. Interobserver agreement for mismatch repair protein immunohistochemistry in endometrial and nonserous, nonmucinous ovarian carcinomas. The American Journal of Surgical Pathology 2019; 43(5):591-600.
  7. McAlpine JN, Temkin SM, Mackay HJ. Endometrial cancer: not your grandmother's cancer. Cancer 2016; 122(18):2787-98.
  8. Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, et al. Current recommendations and recent progress in endometrial cancer. CA: a cancer journal for clinicians 2019; 69(4):258-79.
  9. Gien L, Kwon J, Oliver TK, Fung-Kee-Fung M. Adjuvant hormonal therapy for stage I endometrial cancer. Current Oncology 2008; 15(3):126-35.
  10. MacKay HJ, Freixinos VR, Fleming GF. Therapeutic targets and opportunities in endometrial cancer: update on endocrine therapy and nonimmunotherapy targeted options. American Society of Clinical Oncology Educational Book 2020; 40:245-55.
  11. Green AK, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer. American Society of Clinical Oncology Educational Book 2020; 40:238-44.
  12. Keller MD, Neppl C, Irmak Y, Hall SR, Schmid RA, Langer R, et al. Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. Modern pathology 2018; 31(1):101-10.
  13. Sungu N, Yildirim M, Desdicioglu R, Aydoğdu ÖB, Kilicarslan A, Doğan HT, et al. Expression of immunomodulatory molecules PD-1, PD-L1, and PD-L2, and their relationship with clinicopathologic characteristics in endometrial cancer. International Journal of Gynecological Pathology 2019; 38(5):404-13.
  14. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubat T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. International immunology 1996; 8(5):765-72.
  15. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science translational medicine 2016; 8(328):328rv4-.
  16. Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, et al. PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity. Cell reports 2017; 20(8):1818-29.
  17. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nature reviews cancer 2012; 12(4):252-64.
  18. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature medicine 2002; 8(8):793-800.
  19. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer 2016; 16(5):275-87.
  20. Hamanishi J, Mandai M, Konishi I. Immune checkpoint inhibition in ovarian cancer. International immunology 2016; 28(7):339-48.
  21. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences 2008; 105(8):3005-10.
  22. Kythreotou A, Siddique A, Mauri FA, Bower M, Pinato DJ. PD-L1. Journal of clinical pathology 2018; 71(3):189-94.
  23. Barroso-Sousa R, Ott PA. PD-1 inhibitors in endometrial cancer. Oncotarget 2017; 8(63):106169-70.
  24. Ono R, Nakayama K, Nakamura K, Yamashita H, Ishibashi T, Ishikawa M, et al. Dedifferentiated endometrial carcinoma could be a target for immune checkpoint inhibitors (anti PD-1/PD-L1 antibodies). International Journal of Molecular Sciences 2019; 20(15):3744.
  25. Post CC, Westermann AM, Bosse T, Creutzberg CL, Kroep JR. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Critical Reviews in Oncology/Hematology 2020; 152:102973.
  26. Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, et al. Association of polymerase e–mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA oncology 2015; 1(9):1319-23.
  27. Liu J, Liu Y, Wang W, Wang C, Che Y. Expression of immune checkpoint molecules in endometrial carcinoma. Experimental and Therapeutic Medicine 2015; 10(5):1947-52.
  28. Hecking T, Thiesler T, Halbe J, Otten L, Recker F, Gevensleben H, et al. Programmed cell death ligand-1 (PDL-1) correlates with tumor infiltration by immune cells and represents a promising target for immunotherapy in endometrial cancer. Anticancer Research 2022; 42(3):1367-76.
  29. Engerud H, Berg HF, Myrvold M, Halle MK, Bjorge L, Haldorsen IS, et al. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic oncology 2020; 157(1):260-7.
  30. Crumley S, Kurnit K, Hudgens C, Fellman B, Tetzlaff MT, Broaddus R. Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Modern Pathology 2019; 32(3):396-404.
  31. Tawadros AI, Khalafalla MM. Expression of programmed death-ligand 1 and hypoxia-inducible factor-1α proteins in endometrial carcinoma. Journal of cancer research and therapeutics 2018; 14(Suppl 5):S1063-9.
  32. Li Z, Joehlin-Price AS, Rhoades J, Ayoola-Adeola M, Miller K, Parwani AV, et al. Programmed death ligand 1 expression among 700 consecutive endometrial cancers: strong association with mismatch repair protein deficiency. International Journal of Gynecologic Cancer 2018; 28(1).
  33. Mo Z, Liu J, Zhang Q, Chen Z, Mei J, Liu L, et al. Expression of PD‑1, PD‑L1 and PD‑L2 is associated with differentiation status and histological type of endometrial cancer. Oncology letters 2016; 12(2):944-50.
  34. Lu L, Li Y, Luo R, Xu J, Feng J, Wang M. Prognostic and clinicopathological role of PD-L1 in endometrial cancer: a meta-analysis. Frontiers in Oncology 2020; 10:632.
  35. Zhang C, Yang Q. Predictive values of programmed cell death-ligand 1 expression for prognosis, clinicopathological factors, and response to programmed cell death-1/programmed cell death-ligand 1 inhibitors in patients with gynecological cancers: a meta-analysis. Frontiers in Oncology 2021; 10:572203.
  36. Mamat@ Yusof MN, Chew KT, Kampan N, Abd. Aziz NH, Md Zin RR, Tan GC, et al. PD-L1 expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis. Cancers 2022; 14(16):3911.
  37. Maiorano BA, Maiorano MF, Cormio G, Maglione A, Lorusso D, Maiello E. How immunotherapy modified the therapeutic scenario of endometrial cancer: a systematic review. Frontiers in Oncology 2022; 12:844801.
مجله زنان، مامایی و نازایی ایران
دوره 27، شماره 10
دی 1403
صفحه 1-16